Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12582637 | Topical formulation for intradermal application and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2039-08-29 | 0 | 31 |
| 12582636 | Pharmaceutical composite formulation comprising proton pump inhibitor and antacid | 🖼🧊📄§ | 2026-03-24 | 2041-01-22 | 0 | 31 |
| 12582634 | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine | 🖼🧊📄§ | 2026-03-24 | 2040-06-10 | 0 | 31 |
| 12582640 | Treatment of lower respiratory tract infection with tradipitant | 🖼🧊📄§ | 2026-03-24 | 2041-03-24 | 0 | 31 |
| 12582641 | Sulfur-containing compound based on glutarimide skeleton and application thereof | 🖼🧊📄§ | 2026-03-24 | 2040-02-25 | 0 | 31 |
| 12582642 | Composition for treating, improving, and/or preventing progression of bovine papillomatosis caused by bovine papillomavirus | 🖼🧊📄§ | 2026-03-24 | 2041-05-28 | 0 | 31 |
| 12582643 | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy | 🖼🧊📄§ | 2026-03-24 | 2041-03-03 | 0 | 31 |
| 12582647 | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | 🖼🧊📄§ | 2026-03-24 | 2044-02-08 | 0 | 31 |
| 12582644 | O-GlcNAc transferase inhibitors and uses thereof | 🖼🧊📄§ | 2026-03-24 | 2039-08-29 | 0 | 31 |
| 12582651 | Pharmaceutical composition comprising tadalafil or pharmaceutically acceptable salt thereof and dutasteride or pharmaceutically acceptable salt thereof exhibiting novel dissolution rate | 🖼🧊📄§ | 2026-03-24 | 2041-12-30 | 0 | 31 |
| 12582653 | Method for treating idiopathic pulmonary fibrosis | 🖼🧊📄§ | 2026-03-24 | 2040-06-24 | 0 | 31 |
| 12582655 | Methods of treating disorders using CSFIR inhibitors | 🖼🧊📄§ | 2026-03-24 | 2045-10-21 | 0 | 31 |
| 12582656 | Nucleotide analogues | 🖼🧊📄§ | 2026-03-24 | 2041-03-23 | 0 | 31 |
| 12582657 | Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | 🖼🧊📄§ | 2026-03-24 | 2043-12-19 | 0 | 31 |
| 12582660 | Inhibitors of the RAS oncoprotein, methods of making and methods of use thereof | 🖼🧊📄§ | 2026-03-24 | 2039-05-10 | 0 | 31 |
| 12582659 | Stimulant composition and process for making same | 🖼🧊📄§ | 2026-03-24 | 2045-09-09 | 0 | 31 |
| 12582667 | Compositions and methods to treat metastatic gastrointestinal cancer | 🖼🧊📄§ | 2026-03-24 | 2040-09-25 | 0 | 31 |
| 12582668 | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | 🖼🧊📄§ | 2026-03-24 | 2040-06-05 | 0 | 31 |
| 12582665 | Topical composition | 🖼🧊📄§ | 2026-03-24 | 2041-04-12 | 0 | 31 |
| 12582674 | Methods and treatment of trauma | 🖼🧊📄§ | 2026-03-24 | 2043-01-09 | 0 | 31 |
| 12582669 | Composition controlling pharmacokinetics in the body | 🖼🧊📄§ | 2026-03-24 | 2044-03-04 | 0 | 31 |
| 12582671 | Water soluble electrolyzed silicon dioxide formulation and method of manufacture | 🖼🧊📄§ | 2026-03-24 | 2043-09-26 | 0 | 31 |
| 12582673 | Extended use zirconium silicate compositions and methods of use thereof | 🖼🧊📄§ | 2026-03-24 | 2043-07-07 | 0 | 31 |
| 12576143 | Teleost invariant chain cancer vaccine | 🖼🧊📄§ | 2026-03-17 | 2039-10-18 | 0 | 31 |
| 12577285 | Process for producing a composition of engineered T cells | 🖼🧊📄§ | 2026-03-17 | 2038-12-07 | 0 | 31 |
| 12577255 | MDM2-based modulators of proteolysis and associated methods of use | 🖼🧊📄§ | 2026-03-17 | 2042-01-06 | 0 | 31 |
| 12577312 | Methods for the treatment of melanoma using compositions of denosumab and PD-1 inhibitor | 🖼🧊📄§ | 2026-03-17 | 2045-02-26 | 0 | 31 |
| 12580049 | Tumor microenvironment-based methods for assessing CAR-T and other immunotherapies | 🖼🧊📄§ | 2026-03-17 | 2042-12-23 | 0 | 31 |
| 12576119 | Bacteriophage compositions and methods for treatment of bacterial infections | 🖼🧊📄§ | 2026-03-17 | 2045-04-14 | 0 | 31 |
| 12576138 | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase | 🖼🧊📄§ | 2026-03-17 | 2039-05-17 | 0 | 31 |
| 12577283 | Knockdown or knockout of one or more of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to mitigate t cell recognition of allogeneic cell products | 🖼🧊📄§ | 2026-03-17 | 2042-01-28 | 0 | 31 |
| 12577325 | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof | 🖼🧊📄§ | 2026-03-17 | 2044-11-22 | 0 | 31 |
| 12577222 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | 🖼🧊📄§ | 2026-03-17 | 2044-01-19 | 0 | 31 |
| 12576129 | Anthelmintic compositions and methods | 🖼🧊📄§ | 2026-03-17 | 2042-09-23 | 0 | 31 |
| 12576057 | Antibacterial and biofilm formation-inhibiting composition containing myristoleic acid as active ingredient | 🖼🧊📄§ | 2026-03-17 | 2042-11-18 | 0 | 31 |
| 12576149 | Gamma delta T cells derived from induced pluripotent stem cells, and production method therefor | 🖼🧊📄§ | 2026-03-17 | 2045-01-14 | 0 | 31 |
| 12576053 | Use of 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl) methylidenejinden-1-yl] acetic acid | 🖼🧊📄§ | 2026-03-17 | 2038-04-11 | 0 | 31 |
| 12576123 | Epitope-based approach for allergy treatments and inhibitors for Crohn's disease | 🖼🧊📄§ | 2026-03-17 | 2040-03-13 | 0 | 31 |
| 12576154 | Conjugates of PSMA-binding moieties with cytotoxic agents | 🖼🧊📄§ | 2026-03-17 | 2043-07-31 | 0 | 31 |
| 12576062 | Methods using administration of medium chain triglycerides (MCT) prior to a meal to increase ketone production from the MCTs | 🖼🧊📄§ | 2026-03-17 | 2040-03-17 | 0 | 31 |
| 12576118 | Bacteriophages for the treatment of tuberculosis | 🖼🧊📄§ | 2026-03-17 | 2040-05-21 | 0 | 31 |
| 12576045 | Methods and nutraceutical compositions for the prevention and/or mitigation of veisalgia | 🖼🧊📄§ | 2026-03-17 | 2043-02-06 | 0 | 31 |
| 12576166 | Contrast agents for detection of enzyme activities based on melanin synthesis | 🖼🧊📄§ | 2026-03-17 | 2041-07-26 | 0 | 31 |
| 12576158 | Antibody drug conjugates with cleavable linkers | 🖼🧊📄§ | 2026-03-17 | 2040-05-22 | 0 | 31 |
| 12576040 | Ionizable lipids and methods of manufacture and use thereof | 🖼🧊📄§ | 2026-03-17 | 2041-10-13 | 0 | 31 |
| 12576140 | Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases | 🖼🧊📄§ | 2026-03-17 | 2041-07-29 | 0 | 31 |
| 12576133 | Antigen-binding agents that specifically bind epidermal growth factor receptor variant III | 🖼🧊📄§ | 2026-03-17 | 2040-03-23 | 0 | 31 |
| 12576083 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | 🖼🧊📄§ | 2026-03-17 | 2044-01-17 | 0 | 31 |
| 12576094 | Combination cannabinoid-phenylethanoid formulation for treatment of inflammation and methods related thereto | 🖼🧊📄§ | 2026-03-17 | 2040-11-20 | 0 | 31 |
| 12576077 | Composition for preventing, alleviating or treating cancer | 🖼🧊📄§ | 2026-03-17 | 2043-08-28 | 0 | 31 |